Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (37.6), the stock would be worth ¥3.06 (53% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 79.6 | ¥6.49 |
0%
|
| 3-Year Average | 37.6 | ¥3.06 |
-53%
|
| 5-Year Average | 29.1 | ¥2.38 |
-63%
|
| Industry Average | 49.4 | ¥4.03 |
-38%
|
| Country Average | 29.6 | ¥2.42 |
-63%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
¥6.6B
|
/ |
Oct 2025
¥83.8m
|
= |
|
|
¥6.6B
|
/ |
Dec 2025
¥404.8m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
B
|
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
|
6.7B CNY | 79.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.1 |
| Median | 29.6 |
| 70th Percentile | 57.7 |
| Max | 43 569.3 |
Other Multiples
Beijing SL Pharmaceutical Co Ltd
Glance View
Beijing SL Pharmaceutical Co Ltd. is a notable player in the pharmaceutical sector, navigating the rigorous demands of healthcare with a focus on innovation and market responsiveness. Born from a deep understanding of the medical field, the company has carved a niche by focusing on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical products. Among its specialties, Beijing SL Pharmaceutical is renowned for its expertise in producing complex chemicals and biologics, which are vital in treating various medical conditions ranging from cardiovascular diseases to neurological disorders. The company puts significant emphasis on research and development, ensuring that its product pipeline remains robust and poised for future growth. The commercial success of Beijing SL Pharmaceutical is largely driven by its keen adaptation to the dynamic healthcare needs both domestically and internationally. The company leverages its extensive distribution network and strategic partnerships with healthcare providers and institutions to ensure that its products reach patients efficiently. By maintaining a diverse product portfolio that caters to pressing medical needs, the company combines patient-centric strategies with astute business acumen to maintain steady revenue streams. Furthermore, its commitment to quality and safety standards reinforces trust among stakeholders, thereby enabling Beijing SL Pharmaceutical to thrive in a competitive landscape. As it continues to expand, the company remains vigilant in enhancing its technological capabilities and market reach, always with an eye on delivering value through health and wellness.